Modulation of LPS-induced pulmonary neutrophil infiltration and cytokine production by the selective PPARβ/δ ligand GW0742

[1]  Rabinder Randhawa,et al.  Acute lung injury , 2007 .

[2]  T. Willson,et al.  PPARβ/δ Protects Against Experimental Colitis Through a Ligand-Independent Mechanism , 2007, Digestive Diseases and Sciences.

[3]  S. Asano,et al.  Expression profiling of Peroxisome proliferator-activated receptor-delta (PPAR-delta) in mouse tissues using tissue microarray , 2007, Histochemistry and Cell Biology.

[4]  P. Baeuerle,et al.  Lipopolysaccharide-induced lung inflammation is inhibited by neutralization of GM-CSF. , 2007, European journal of pharmacology.

[5]  Arya M. Sharma,et al.  Peroxisome Proliferator-Activated Receptor γ and Adipose Tissue—Understanding Obesity-Related Changes in Regulation of Lipid and Glucose Metabolism , 2007 .

[6]  N. Frossard,et al.  Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases? , 2006, Fundamental & clinical pharmacology.

[7]  J. Hamilton,et al.  Therapeutic potential of treating chronic obstructive pulmonary disease (COPD) by neutralising granulocyte macrophage-colony stimulating factor (GM-CSF). , 2006, Pharmacology & therapeutics.

[8]  Lihong Cheng,et al.  PPARδ modulates lipopolysaccharide-induced TNFα inflammation signaling in cultured cardiomyocytes , 2006 .

[9]  T. van der Poll,et al.  Pulmonary Lipopolysaccharide (LPS)-Binding Protein Inhibits the LPS-Induced Lung Inflammation In Vivo1 , 2006, The Journal of Immunology.

[10]  L. Stoll,et al.  Peroxisome Proliferator‐Activated Receptors: Potential Therapeutic Targets in Lung Disease? , 2006, Pediatric pulmonology.

[11]  W. Wahli,et al.  PPARs in diseases: control mechanisms of inflammation. , 2005, Current medicinal chemistry.

[12]  S. Yao,et al.  Rosiglitazone, an agonist of peroxisome proliferator-activated receptor γ, reduces pulmonary inflammatory response in a rat model of endotoxemia , 2005, Inflammation Research.

[13]  J. Auwerx,et al.  PPARα downregulates airway inflammation induced by lipopolysaccharide in the mouse , 2005, Respiratory research.

[14]  T. Graham,et al.  The PPARδ agonist GW0742X reduces atherosclerosis in LDLR−/− mice , 2005 .

[15]  E. Mazzon,et al.  Effect of rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J2 on bleomycin-induced lung injury , 2005, European Respiratory Journal.

[16]  S. Young,et al.  Transcriptional Profiling of Lipopolysaccharide-Induced Acute Lung Injury , 2004, Infection and Immunity.

[17]  M. Belvisi,et al.  PPAR‐γ agonists as therapy for diseases involving airway neutrophilia , 2004, European Respiratory Journal.

[18]  T. Willson,et al.  Peroxisome Proliferator-Activated Receptor (PPAR)-β/δ Stimulates Differentiation and Lipid Accumulation in Keratinocytes , 2004 .

[19]  J. Gomez-Cambronero,et al.  Granulocyte-Macrophage Colony-Stimulating Factor Is a Chemoattractant Cytokine for Human Neutrophils: Involvement of the Ribosomal p70 S6 Kinase Signaling Pathway 1 , 2003, The Journal of Immunology.

[20]  K. Kristiansen,et al.  Expression and localization of peroxisome proliferator-activated receptors and nuclear factor kappaB in normal and lesional psoriatic skin. , 2003, The Journal of investigative dermatology.

[21]  P. Whittaker,et al.  PPAR‐α and ‐γ but not ‐δ agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF‐κB‐independent effect , 2003 .

[22]  John A. Hamilton,et al.  Granulocyte/Macrophage-Colony-stimulating Factor (GM-CSF) Regulates Lung Innate Immunity to Lipopolysaccharide through Akt/Erk Activation of NFκB and AP-1 in Vivo * , 2002, The Journal of Biological Chemistry.

[23]  E. Jabłońska.  Effect of soluble interleukin-6 receptor alpha and interleukin-6 secreted by polymorphonuclear leukocytes on tumor necrosis factor-alpha expression and its production by peripheral blood mononuclear cells. , 2002, Mediators of inflammation.

[24]  B. Staels,et al.  PPARs: Transcription Factors Controlling Lipid and Lipoprotein Metabolism , 2002, Annals of the New York Academy of Sciences.

[25]  F. Colpaert,et al.  PPARα and PPARδ activators inhibit cytokine-induced nuclear translocation of NF-κB and expression of VCAM-1 in EAhy926 endothelial cells , 2002 .

[26]  W. Wahli,et al.  Critical roles of PPARβ/δ in keratinocyte response to inflammation , 2001 .

[27]  S. Kliewer,et al.  A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[28]  I. Saluja,et al.  PPAR δ agonists stimulate oligodendrocyte differentiation in tissue culture , 2001 .

[29]  J. Hansen,et al.  Peroxisome Proliferator-activated Receptor δ (PPARδ)-mediated Regulation of Preadipocyte Proliferation and Gene Expression Is Dependent on cAMP Signaling* , 2001, The Journal of Biological Chemistry.

[30]  M. Peters-Golden,et al.  GM-CSF Regulates Bleomycin-Induced Pulmonary Fibrosis Via a Prostaglandin-Dependent Mechanism , 2000, The Journal of Immunology.

[31]  T. Willson,et al.  The PPARs: from orphan receptors to drug discovery. , 2000, Journal of medicinal chemistry.

[32]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: nuclear control of metabolism. , 1999, Endocrine reviews.

[33]  P. Ward,et al.  Role for macrophage inflammatory protein-2 in lipopolysaccharide-induced lung injury in rats. , 1996, Journal of immunology.

[34]  J. Paulauskis,et al.  Expression of macrophage inflammatory protein-2 and KC mRNA in pulmonary inflammation. , 1992, The American journal of pathology.

[35]  Christopher K. Glass,et al.  Combinatorial roles of nuclear receptors in inflammation and immunity , 2006, Nature Reviews Immunology.

[36]  M. Vázquez-Carrera,et al.  Nuclear factor-kappaB activation leads to down-regulation of fatty acid oxidation during cardiac hypertrophy. , 2005, The Journal of biological chemistry.

[37]  J. Berger,et al.  The mechanisms of action of PPARs. , 2002, Annual review of medicine.